Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | NNMT | P40261 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12204514 | 0.78 | HDAC1 (0.52) | DGAT1MAPK1KDM4EL3MBTL1HDAC6 | |
| SCHEMBL15375343 | 0.78 | DGAT1 (0.34) | DGAT1NNMTHDAC6HDAC1FDFT1 | |
| SCHEMBL424411 | 0.77 | MAPK1 (0.65) | MAPK1NNMTKDM4EL3MBTL1NOTUM | |
| SCHEMBL2277833 | 0.77 | DGAT1 (0.69) | DGAT1L3MBTL1MAPT | |
| SCHEMBL14061762 | 0.76 | HDAC1 (0.36) | DGAT1HDAC6HDAC1FDFT1 | |
| SCHEMBL22230063 | 0.74 | FDFT1 (0.33) | DGAT1NNMTHDAC6HDAC1FDFT1 | |
| SCHEMBL3123911 | 0.73 | DGAT1 (0.39) | DGAT1NNMTHDAC6HDAC1FDFT1 | |
| SCHEMBL9603059 | 0.73 | MAPT (0.45) | MAPK1L3MBTL1NOTUMMAPT | |
| Hydrochloric Acid SCHEMBL23906966 | 0.72 | UBE2T (0.47) | PRSS1PRSS2PRSS3 | |
| SCHEMBL7341364 | 0.72 | DGAT1 (0.45) | DGAT1MAPK1L3MBTL1HDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3911640-B1 | PCSK9 INHIBITORS FOR USE IN THERAPY, ESPECIALLY THE TREATMENT OF CARDIOVASCULAR DISEASE | ASTRAZENECA AB (SE) | 2026-05-13 | — | — | EP | disclosed |
| US-12552807-B2 | PCSK9 inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2026-02-17 | — | — | US | disclosed |
| EP-4470609-A2 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2024-12-04 | — | — | EP | disclosed |
| EP-3911648-B1 | 6'-[[(1S,3S)-3-[[5-(DIFLUOROMETHOXY)-2-PYRIMIDINYL]AMINO]CYCLOPENTYL]AMINO][1(2H),3'-BIPYRIDIN]-2-ONE AS PCSK9 INHIBITOR AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-10-23 | — | — | EP | disclosed |
| US-11603523-B2 | PCSK9 inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2023-03-14 | — | — | US | disclosed |
| US-20220220122-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2022-07-14 | — | — | US | disclosed |
| US-11248001-B2 | PCSK9 inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2022-02-15 | — | — | US | disclosed |
| EP-3911648-A2 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2021-11-24 | — | — | EP | disclosed |
| EP-3911640-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2021-11-24 | — | — | EP | disclosed |
| US-20200291041-A1 | PCSK9 Inhibitors and Methods of Use Thereof | ASTRAZENECA AB (SE) | 2020-09-17 | — | — | US | disclosed |
| US-20200231584-A1 | PCSK9 Inhibitors and Methods of Use Thereof | ASTRAZENECA AB (SE) | 2020-07-23 | — | — | US | disclosed |
| WO-2020150474-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | DOGMA THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| WO-2020150473-A2 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | DOGMA THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| WO-2020150473-A2 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | DOGMA THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| WO-2020150474-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | DOGMA THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11248001-B2 | PCSK9 inhibitors and methods of use thereof | PCSK9, PCSK7, PCSK6 | DGAT1 289/4885MAPK1 1645/4885NNMT 3104/4885 |
| US-20200291041-A1 | PCSK9 Inhibitors and Methods of Use Thereof | PCSK9, PCSK7, PCSK6 | DGAT1 324/4885MAPK1 2255/4885NNMT 2497/4885 |
| US-12552807-B2 | PCSK9 inhibitors and methods of use thereof | PCSK9, PCSK7, PCSK6 | DGAT1 695/4885MAPK1 2067/4885NNMT 3553/4885 |
| US-11603523-B2 | PCSK9 inhibitors and methods of use thereof | PCSK9, PCSK7, PCSK6 | DGAT1 302/4885MAPK1 3495/4885NNMT 2161/4885 |
| US-20200231584-A1 | PCSK9 Inhibitors and Methods of Use Thereof | PCSK9, PCSK7, PCSK6 | DGAT1 302/4885MAPK1 3495/4885NNMT 2161/4885 |
| US-20220220122-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | DGAT1 324/4885MAPK1 2255/4885NNMT 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.